Isomorphic Labs Powers AI Drug Discovery Toward Clinical Trials

Isomorphic Labs has secured $5 billion to push AI-designed medicines closer to patients. The company announced the Series C funding on November 17, 2026, giving its drug-design engine and clinical plans a major new source of momentum.
The oversubscribed round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz and Alphabet also participating. Every existing investor returned, bringing Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund back into the company’s next phase.
A $5 Billion Bet on AI-Designed Medicines
Isomorphic Labs will use the funding to expand IsoDDE, its proprietary drug-design engine, while building the infrastructure needed to move discoveries toward patient testing. The company plans to expand into new areas of biology and create global infrastructure for AI-led bioengineering.
At the center of that effort sits IsoDDE, a collection of AI simulation models built for different therapeutic areas and drug types. The system searches chemical space to design and refine molecules with drug-like properties, while proprietary agents navigate and reason through complex biology.
That combination aims to turn AI from a research tool into a system for creating therapeutic candidates. Isomorphic is also building a partner ecosystem to study the mechanisms that drive disease, adding a broader biological research layer to its drug-design work.
The company will build translational and clinical-development infrastructure as well. That infrastructure will help move research toward patient testing and support candidates that approach clinical trials.
Founder and CEO Demis Hassabis described the goal in the funding release: “When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI.”
From Molecular Models to Clinical Programs
Isomorphic reports positive preclinical outcomes from wholly owned oncology and immunology programs, as well as from partnered work. Those results provide the basis for the company’s planned move toward clinical trials, where AI-generated designs will face the demands of real-world medicine.
Hassabis said the new capital will support three linked priorities: “building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”
The company’s partnership portfolio already connects its platform with major pharmaceutical businesses:
- Novartis began working with Isomorphic in January 2024 on small molecules against three challenging targets.
- Eli Lilly is collaborating with Isomorphic on small-molecule therapeutics against undisclosed targets.
- Johnson & Johnson has a multi-target collaboration spanning small molecules and biologics.
These collaborations give Isomorphic routes to apply its models across different drug types and disease targets. The company’s own pipeline and partner programs now provide the testing ground for its larger ambition: using AI to design the next generation of medicines.
A Rapid Funding Climb for Isomorphic Labs
The Series C follows a $2.1 billion Series B announced on May 12, 2026, led by Thrive Capital. Alphabet and GV participated in that round alongside MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
Before that, Thrive led Isomorphic’s first external round of $600 million, announced on March 31, 2025. GV and follow-on capital from Alphabet also participated in that financing, giving the startup a strong investor base before its latest raise.
Hassabis has led Isomorphic Labs as CEO since the startup spun out of DeepMind in 2021. The Series C arrives three-and-a-half months after he stepped back as CEO of DeepMind, Google’s AI lab, which he co-founded before Google acquired it in 2014.
The size of the round also lands during a powerful funding cycle for AI-driven drug discovery. Drug discovery startups raised $23.2 billion in 2026, according to Dealroom, a record figure.
Isomorphic’s funding gives the company room to work across the full path from molecular design to clinical development. Its next challenge is to convert that financial firepower, its AI models and its partnerships into therapeutic programs that can reach trials and deliver results for patients.
The company now has a clear target: build deeper models of biology, expand its drug-design engine and move its first therapeutic programs toward clinical testing. The next stage will show whether AI can turn that vision into medicines.
Based on
- Isomorphic Labs Raises $5B Series C to Advance AI Drug Design — unite.ai
- Ex-Google DeepMind CEO Demis Hassabis’ AI company raises $5 billion — cnbc.com
- Plural Raises €1bn to Back the Frontier Founders Building a New Europe | AFP.com — origin-zh9p7m-www.afp.com
- Menlo Ventures’ 2026 State of AI in Healthcare Report: Healthcare AI Spending Hits $3.7B, Up 2.5x as Growth Shifts From Paperwork to Drug Discovery and Patient Care | Markets Insider — markets.businessinsider.com
- Iambic Provides Business Updates and Third Quarter 2026 Financial Results | Markets Insider — markets.businessinsider.com




